Economic Evaluation and Added Value for Stakeholders of Switching From Rituximab Intravenous Injection to Rituximab Subcutaneous Injection In France
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.2418
https://www.valueinhealthjournal.com/article/S1098-3015(15)04494-0/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
1829
First Page :
A664
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04494-0&doi=10.1016/j.jval.2015.09.2418